Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

OSE Immunotherapeutics - Filing #880997

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	57 670 EUR	—	—	—	—	—	—	—	57 141 EUR	—	—	—	—	—
Current assets	44 206 EUR	—	—	—	—	—	—	—	39 832 EUR	—	—	—	—	—
Non-current liabilities	37 224 EUR	—	—	—	—	—	—	—	21 481 EUR	—	—	—	—	—
Current liabilities	16 761 EUR	—	—	—	—	—	—	—	14 128 EUR	—	—	—	—	—
Revenue	—	—	—	—	—	—	26 306 EUR	—	—	10 432 EUR	—	—	—	—
Profit (loss)	—	16 850 EUR	—	—	—	—	16 850 EUR	—	—	16 555 EUR	—	—	—	16 555 EUR
Other comprehensive income	—	—	—	—	—	—	29,000 EUR	—	—	7,000 EUR	—	—	—	—
Comprehensive income	—	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR	0 EUR	—	16 561 EUR	4,000 EUR	0 EUR	0 EUR	16 558 EUR